Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

NCT02651727 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped the company's decision to de-prioritize 4718 development

Conditions

Pancreatic Cancer

Interventions

DRUG: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine
DRUG: Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine
DRUG: Part A- VS-4718, nab-paclitaxel, gemcitabine

Sponsor

Verastem, Inc.